Most Read Articles
01 Aug 2016
Tigecycline is effective against Acinetobacter spp. and Stenotrophomonas maltophilia, based on the SENTRY Antimicrobial Surveillance Program.
02 Apr 2018
JARDIANCE® (Empagliflozin)
Boehringer Ingelheim (Malaysia) Sdn Bhd
    
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

Pearl Toh, 10 Jul 2018
A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.

Triple drug combo effective for lowering blood pressure, LDL-C levels

03 Dec 2017

Treatment with triple combination of amlodipine, losartan and rosuvastatin appears to be an effective therapeutic strategy for lowering blood pressure (BP) and low-density lipoprotein (LDL)-C levels in patients with comorbid hypertension and dyslipidaemia, according to a study.

A total of 146 patients with a sitting diastolic blood pressure (SiDBP) of >90 mm Hg and LDL-C levels <250 mg/dL were randomized to one the following treatment regimens: losartan potassium 100 mg plus rosuvastatin 20 mg (L/R group), amlodipine camsylate 5 mg plus losartan potassium 100 mg (A/L group), and amlodipine 5 mg plus losartan potassium 100 mg plus rosuvastatin 20 mg (A/L/R group).

The 8-week treatment was initiated after a 4-week run-in period during which patients underwent therapeutic lifestyle changes and took losartan potassium 100 mg once daily, with a goal to achieve blood pressure criteria (80 mm Hg ≤ SiDBP < 110 mm Hg) and the LDL-C level criteria.

Of the patients, 138 completed treatment and 143 were included in the full analysis. After 8 weeks, A/L/R yielded a significantly greater mean percent change in LDL-C compared with L/R (–48.40 vs –6.70 percent; p<0.0001). Likewise, the mean change in SiDBP was significantly greater with A/L/R vs A/L (–9.75 vs –1.73 mm Hg; p<0.0001).

Researchers noted that LDL-C and SiDBP reductions in the A/L/R group were comparable to reductions in the L/R and A/L groups, respectively.

With respect to safety, 10 adverse events occurred in seven patients, including three in the A/L/R group, two in the A/L group and another two in the L/R group. Tachycardia and face oedema were considered adverse drug reactions, but these events were mild and resolved without specific treatment. No clinically significant tolerability issues were reported during the treatment period.

Findings of the present study “will form the foundation of the future development of a single-pill triple combination,” researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Aug 2016
Tigecycline is effective against Acinetobacter spp. and Stenotrophomonas maltophilia, based on the SENTRY Antimicrobial Surveillance Program.
02 Apr 2018
JARDIANCE® (Empagliflozin)
Boehringer Ingelheim (Malaysia) Sdn Bhd
    
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

Pearl Toh, 10 Jul 2018
A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.